Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: Bedrock who wrote (700)	6/8/1998 11:41:00 PM
From: Sleepman	Respond to of 834

I agree. I have looked into the literature on this drug,and it seems to me to be an effective anticoagulant that will develop a strong place in the market. It is probably as safe as many other anticoagulants. Also, I think that there will be serious money in TXB's endothelin antagonists. They may be helpful in treating heart failure, but most certainly will be a novel approach to treating primary pulmonary hypertension, a disease that remains nearly always fatal if the patient does not receive a lung transplant. Dan